Male breast cancer patients stop taking tamoxifen early because of drug-related side effects

November 16, 2011 in Cancer

The largest study to investigate the tolerability of the breast cancer drug tamoxifen in male breast cancer patients has shown that men stop taking their prescribed therapy early because of problems with side effects caused by the drug.

The authors of the research paper, published today in the cancer journal Annals of Oncology, looked at records of 64 patients at their institution who had received for an average of four years and found that 53% (34) of the patients experienced one or more drug-related . Of these 64 patients, 20.3% (13) of the discontinued taking their prescribed tamoxifen therapy early because of the side effects. The research suggests that male patients who discontinue tamoxifen therapy early may have an increased risk of the cancer recurring.

Male breast cancer is a rare disease and the world age-standardised incidence rate is 0.4 per 100,000 in men compared with 66.7 per 100,000 in women. Tamoxifen is the standard of care for the hormone treatment of men with breast cancer and works by blocking the growth-promoting action of the hormone oestrogen on the . Almost all (90%) breast cancers in men are hormone-receptor-positive and drugs that target the are usually given after surgery.

Dr Naveen Pemmaraju, who carried out the research under the direction of Dr Sharon Giordano at the Department of Breast at the University of Texas MD Anderson Cancer Center, Houston, USA, said "This is the largest study to specifically assess tamoxifen-related side effects in men because in our institution we treated a relatively large number of male breast . We found that, after adjusting for patient age and stage of the disease, the prognosis for men with breast cancer is similar to that of women. Tamoxifen has been shown to improve for breast cancer patients, so early discontinuations may have the potential to increase the risk of the cancer recurring in this group of male breast cancer patients.

"Male breast cancer is a very rare and unique cancer affecting approximately 2,000 men in the USA per year. As there are so few male breast cancer cases, clinical practice and optimal treatment strategies have been extrapolated from female breast cancer patients with very little published evidence to guide clinical decisions. In our institution, we noted that several of our male patients were having difficulty with taking , and these side effects appeared to be a little bit different to those reported with women receiving the same drug."

Weight gain and loss of sex drive were the most frequently occurring tamoxifen-related side effects observed in the study. Of the 13 male patients who stopped taking tamoxifen early because of side effects, four of the discontinuation decisions (31%) were physician-directed (four thromboembolic events) and nine (69%) were patient-directed preferences based on the intolerable side-effects. Nine patients died after stopping tamoxifen early in the study.

Dr Pemmaraju said: "Tamoxifen is a hormonal treatment, specifically an anti-oestrogen. We think that men might experience some different side effects than women because men have a different hormonal environment than women (for instance they have more testosterone and less oestrogen). This difference in hormone levels could result in different side effects when using a drug that blocks hormones.

"The results of this study should not change the recommendation for prescribing tamoxifen for male breast cancer patients. However, clinicians need to be aware of the possible side effects that men may experience when receiving tamoxifen so that the patients can be counselled appropriately," Dr Pemmaraju added. "This study also highlights the importance of funding and conducting research for rare disease so that we understand the true toxicities and benefits of treatment.

"Our next step will be to prospectively collect data on the side effects that men get when they are prescribed to take tamoxifen for breast cancer. This follow-up study will be very important because it will provide much more detailed and comprehensive information on the tolerability profile of tamoxifen in male ," Dr Pemmaraju concluded.

Male breast cancer is very rare and statistical records are not available for most European countries. In the UK, around 300 men are diagnosed with breast cancer each year compared with about 45,700 cases in women. In the US in 2011, about 2,140 new cases of invasive breast cancer will be diagnosed in men compared with 230,480 new cases in women and approximately 450 men will die from breast cancer compared with 39,520 women.

Journal reference: Annals of Oncology search and more info website

Provided by European Society for Medical Oncology

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

New fluorescent tools for cancer diagnosis

In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...

Cancer created 41 minutes ago | popularity not rated yet | comments 0

Modulating the immune system to combat metastatic cancer

Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...

Cancer created 43 minutes ago | popularity not rated yet | comments 0

Scientists put bowel cancer under the microscope

Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.

Cancer created 3 hours ago | popularity 5 / 5 (1) | comments 0

Researcher identifies breast cancer fighting hormone

Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.

Cancer created 4 hours ago | popularity 5 / 5 (1) | comments 0

Ground breaking cancer research finds immune system link

(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.

Cancer created 4 hours ago | popularity 5 / 5 (2) | comments 0


Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.

Storm chasers: born to be wild?

(HealthDay)—We've all seen them: the surfers who race to the beach when a hurricane hits, the guy who decides to ride out the storm in his overmatched boat, the tornado chasers who fearlessly steer their ...

Bulletin provides guidelines for second-trimester abortion

(HealthDay)—New evidence-based guidelines provide guidance on medical and surgical methods for second-trimester abortion and management of associated complications, according to a practice bulletin published ...

Top-ranked golfer beats scoliosis

(HealthDay)—As a world-class golfer, Stacy Lewis' accomplishments are remarkable. But it was a physical challenge in her childhood that defined her ascent to the top of her sport.

Going live: Immune cell activation in multiple sclerosis

Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...

ACOG: Hormone therapy not recommended to prevent CHD

(HealthDay)—Menopausal hormone therapy should not be used for prevention of coronary heart disease, according to a Committee Opinion from the American College of Obstetricians and Gynecologists (ACOG) published ...